Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells

Feiran Zhang,Shridhar Bhat,Sandra B Gabelli,Xiaochun Chen,Michelle S Miller,Benjamin A Nacev,Yim Ling Cheng,David J Meyers,Karen Tenney,Joong Sup Shim,Phillip Crews,L Mario Amzel,Dawei Ma,Jun O Liu
DOI: https://doi.org/10.1021/jm400227z
2013-05-23
Abstract:Methionine aminopeptidases (MetAPs), which remove the initiator methionine from nascent peptides, are essential in all organisms. While MetAP2 has been demonstrated to be a therapeutic target for inhibiting angiogenesis in mammals, MetAP1 seems to be vital for cell proliferation. Our earlier efforts identified two structural classes of human MetAP1 (HsMetAP1)-selective inhibitors (1-4), but all of them failed to inhibit cellular HsMetAP1. Using Mn(II) or Zn(II) to activate HsMetAP1, we found that 1-4 could only effectively inhibit purified HsMetAP1 in the presence of physiologically unachievable concentrations of Co(II). In an effort to seek Co(II)-independent inhibitors, a novel structural class containing a 2-(pyridin-2-yl)quinazoline core has been discovered. Many compounds in this class potently and selectively inhibited HsMetAP1 without Co(II). Subsequently, we demonstrated that 11j, an auxiliary metal-dependent inhibitor, effectively inhibited HsMetAP1 in primary cells. This is the first report that an HsMetAP1-selective inhibitor is effective against its target in cells.
What problem does this paper attempt to address?